ISCHSTR
MCID: STR067
MIFTS: 79

Stroke, Ischemic (ISCHSTR)

Categories: Cardiovascular diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Stroke, Ischemic

MalaCards integrated aliases for Stroke, Ischemic:

Name: Stroke, Ischemic 57 40 37
Cerebral Infarction 57 40 12 72 54 44 15 70 32
Stroke 57 53 54 6 42 3 62 17
Cerebral Infarction, Susceptibility to 57 29 13 6
Cerebrovascular Accident 57 40 72 70
Ischemic Stroke 57 72 42 70
Ischemic Stroke, Susceptibility to 57 29 6
Stroke, Ischemic, Susceptibility to 57 39
Cerebral Infarct 12 15
Ischemic Cerebrovascular Accident 70
Stroke, Susceptibility to 57
Cva - Cerebral Infarction 12
Ischstr 72

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
multifactorial predisposition


HPO:

31
stroke, ischemic:
Inheritance multifactorial inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:3526
OMIM® 57 601367
MeSH 44 D002544
NCIt 50 C50486
SNOMED-CT 67 195188006
SNOMED-CT via HPO 68 230690007
UMLS 70 C0007785 C0038454 C0948008 more

Summaries for Stroke, Ischemic

MedlinePlus : 42 What is a stroke? A stroke happens when there is a loss of blood flow to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die within a few minutes. This can cause lasting brain damage, long-term disability, or even death. If you think that you or someone else is having a stroke, call 911 right away. Immediate treatment may save someone's life and increase the chances for successful rehabilitation and recovery. What are the types of stroke? There are two types of stroke: Ischemic stroke is caused by a blood clot that blocks or plugs a blood vessel in the brain. This is the most common type; about 80 percent of strokes are ischemic. Hemorrhagic stroke is caused by a blood vessel that breaks and bleeds into the brain Another condition that's similar to a stroke is a transient ischemic attack (TIA). It's sometimes called a "mini-stroke." TIAs happen when the blood supply to the brain is blocked for a short time. The damage to the brain cells isn't permanent, but if you have had a TIA, you are at a much higher risk of having a stroke. Who is at risk for a stroke? Certain factors can raise your risk of a stroke. The major risk factors include High blood pressure. This is the primary risk factor for a stroke. Diabetes. Heart diseases. Atrial fibrillation and other heart diseases can cause blood clots that lead to stroke. Smoking. When you smoke, you damage your blood vessels and raise your blood pressure. A personal or family history of stroke or TIA. Age. Your risk of stroke increases as you get older. Race and ethnicity. African Americans have a higher risk of stroke. There are also other factors that are linked to a higher risk of stroke, such as Alcohol and illegal drug use Not getting enough physical activity High cholesterol Unhealthy diet Having obesity What are the symptoms of stroke? The symptoms of stroke often happen quickly. They include Sudden numbness or weakness of the face, arm, or leg (especially on one side of the body) Sudden confusion, trouble speaking, or understanding speech Sudden trouble seeing in one or both eyes Sudden difficulty walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause If you think that you or someone else is having a stroke, call 911 right away. How are strokes diagnosed? To make a diagnosis, your health care provider will Ask about your symptoms and medical history Do a physical exam, including a check of Your mental alertness Your coordination and balance Any numbness or weakness in your face, arms, and legs Any trouble speaking and seeing clearly Run some tests, which may include Diagnostic imaging of the brain, such as a CT scan or MRI Heart tests, which can help detect heart problems or blood clots that may have led to a stroke. Possible tests include an electrocardiogram (EKG) and an echocardiography. What are the treatments for stroke? Treatments for stroke include medicines, surgery, and rehabilitation. Which treatments you get depend on the type of stroke and the stage of treatment. The different stages are Acute treatment, to try to stop a stroke while it is happening Post-stroke rehabilitation, to overcome the disabilities caused by the stroke Prevention, to prevent a first stroke or, if you have already had one, prevent another stroke Acute treatments for ischemic stroke are usually medicines: You may get tPA, (tissue plasminogen activator), a medicine to dissolve the blood clot. You can only get this medicine within 4 hours of when your symptoms started. The sooner you can get it, the better your chance of recovery. If you cannot get that medicine, you may get medicine that helps stop platelets from clumping together to form blood clots. Or you may get a blood thinner to keep existing clots from getting bigger. If you have carotid artery disease, you may also need a procedure to open your blocked carotid artery Acute treatments for hemorrhagic stroke focus on stopping the bleeding. The first step is to find the cause of bleeding in the brain. The next step is to control it: If high blood pressure is the cause of bleeding, you may be given blood pressure medicines. If an aneurysm if the cause, you may need aneurysm clipping or coil embolization. These are surgeries to prevent further leaking of blood from the aneurysm. It also can help prevent the aneurysm from bursting again. If an arteriovenous malformation (AVM) is the cause of a stroke, you may need an AVM repair. An AVM is a tangle of faulty arteries and veins that can rupture within the brain. An AVM repair may be done through Surgery Injecting a substance into the blood vessels of the AVM to block blood flow Radiation to shrink the blood vessels of the AVM Stroke rehabilitation can help you relearn skills you lost because of the damage. The goal is to help you become as independent as possible and to have the best possible quality of life. Prevention of another stroke is also important, since having a stroke increases the risk of getting another one. Prevention may include heart-healthy lifestyle changes and medicines. Can strokes be prevented? If you have already had a stroke or are at risk of having a stroke, you can make some heart-healthy lifestyle changes to try to prevent a future stroke: Eating a heart-healthy diet Aiming for a healthy weight Managing stress Getting regular physical activity Quitting smoking Managing your blood pressure and cholesterol levels If these changes aren't enough, you may need medicine to control your risk factors. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Stroke, Ischemic, also known as cerebral infarction, is related to sneddon syndrome and cerebrovascular disease, and has symptoms including seizures, tremor and back pain. An important gene associated with Stroke, Ischemic is F5 (Coagulation Factor V), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Selenium Micronutrient Network. The drugs Acenocoumarol and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include Bone and Brain, and related phenotypes are stroke and homeostasis/metabolism

Disease Ontology : 12 A cerebrovascular disease that is characterized by an area of necrotic tissue in the brain resulting from a blockage or narrowing in the arteries supplying blood and oxygen to the brain.

OMIM® : 57 A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. It is said to be the third leading cause of death in the United States. Gunel and Lifton (1996) noted that about 20% of strokes are hemorrhagic, resulting in bleeding into the brain. Ischemic strokes, resulting from vascular occlusion, account for the majority of strokes. Bersano et al. (2008) reviewed genetic polymorphisms that have been implicated in the development of stroke. Candidate genes include those involved in hemostasis (see, e.g., F5; 612309), the renin-angiotensin-aldosterone system (see, e.g., ACE; 106180), homocysteine (see, e.g., MTHFR; 607093), and lipoprotein metabolism (see, e.g., APOE; 107741). See also hemorrhagic stroke, or intracerebral hemorrhage (ICH; 614519). (601367) (Updated 20-May-2021)

CDC : 3 A stroke, sometimes called a brain attack, occurs when something blocks blood supply to part of the brain or when a blood vessel in the brain bursts. In either case, parts of the brain become damaged or die. A stroke can cause lasting brain damage, long-term disability, or even death. Learn more about what causes stroke and what happens during a stroke.

NINDS : 53 A stroke occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when they no longer receive oxygen and nutrients from the blood or there is sudden bleeding into or around the brain. The symptoms of a stroke include sudden numbness or weakness, especially on one side of the body; sudden confusion or trouble speaking or understanding speech; sudden trouble seeing in one or both eyes; sudden trouble with walking, dizziness, or loss of balance or coordination; or sudden severe headache with no known cause. There are two forms of stroke: ischemic - blockage of a blood vessel supplying the brain, and hemorrhagic - bleeding into or around the brain.

UniProtKB/Swiss-Prot : 72 Ischemic stroke: A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.

PubMed Health : 62 About stroke: A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked. Without oxygen, brain cells start to die after a few minutes. Sudden bleeding in the brain also can cause a stroke if it damages brain cells. If brain cells die or are damaged because of a stroke, symptoms occur in the parts of the body that these brain cells control. Examples of stroke symptoms include sudden weakness; paralysis or numbness of the face, arms, or legs (paralysis is an inability to move); trouble speaking or understanding speech; and trouble seeing. A stroke is a serious medical condition that requires emergency care. A stroke can cause lasting brain damage, long-term disability, or even death. If you think you or someone else is having a stroke, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts.

Wikipedia : 73 A stroke is a medical condition in which poor blood flow to the brain causes cell death. There are two... more...

Related Diseases for Stroke, Ischemic

Diseases related to Stroke, Ischemic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2236)
# Related Disease Score Top Affiliating Genes
1 sneddon syndrome 33.3 SERPINC1 F5 F2 APOH
2 cerebrovascular disease 33.3 PLAT NOTCH3 MTHFR F5 F2 APOH
3 porencephaly 32.4 NOTCH3 MTHFR F5 F2
4 retinal vascular occlusion 32.4 SERPINC1 MTHFR F5 F3 F2 APOH
5 behcet syndrome 32.1 SERPINC1 MTHFR F5 F2 APOH ACE
6 gaucher's disease 32.0 MTHFR F5 F2 ACE
7 carotid artery occlusion 32.0 PLAT NOS3 LDLR F5 APOH
8 abducens nerve disease 31.9 SERPINC1 F2
9 moyamoya disease 1 31.8 SERPINC1 PLAT NOTCH3 MTHFR F3 F2
10 col4a1-related familial vascular leukoencephalopathy 31.8 NOTCH3 MT-TL1
11 patent foramen ovale 31.7 SERPINC1 PLAT NOTCH3 MTHFR FBN1 F5
12 thrombosis 31.7 SERPINC1 PLAT MTHFR F5 F3 F2
13 cerebral sinovenous thrombosis 31.7 MTHFR F5 F3 F2 APOH
14 atherosclerosis susceptibility 31.6 NOS3 MTHFR F3 CDKN2B-AS1 ACE
15 cardiovascular system disease 31.6 SERPINC1 PLAT NOS3 MTHFR LDLR F3
16 hydrocephalus 31.6 PLAT PIK3CA MTHFR ACE
17 myocardial infarction 31.5 SERPINC1 PLAT NOS3 MTHFR MIAT F5
18 vascular disease 31.4 SERPINC1 PLAT NOS3 MTHFR F5 F3
19 peripheral vascular disease 31.4 SERPINC1 PLAT MTHFR F5 F3 F2
20 pulmonary embolism 31.4 SERPINC1 PLAT MTHFR F5 F3 F2
21 acute myocardial infarction 31.3 SERPINC1 PLAT F3 CDKN2B-AS1 ACE
22 antithrombin iii deficiency 31.3 SERPINC1 MTHFR F5 F2 APOH
23 transient cerebral ischemia 31.3 NOTCH3 MTHFR APOH
24 endocarditis 31.3 SERPINC1 PLAT F2 APOH
25 basilar artery occlusion 31.3 PLAT F2
26 nonbacterial thrombotic endocarditis 31.3 SERPINC1 F3 F2 APOH
27 retinal artery occlusion 31.3 SERPINC1 MTHFR F5 F2 APOH ACE
28 branch retinal artery occlusion 31.3 SERPINC1 MTHFR F3 F2 APOH
29 intracranial aneurysm 31.3 PLAT NOS3 CDKN2B-AS1 ACE
30 aortic dissection 31.2 LDLR FBN1 ACE
31 antiphospholipid syndrome 31.2 SERPINC1 PLAT MTHFR F5 F3 F2
32 sickle cell anemia 31.2 NOS3 MTHFR F2 ACE
33 peripheral artery disease 31.2 NOS3 F3 CDKN2B-AS1 ACE
34 mitral valve disease 31.2 NOS3 FBN1 F3 F2 ACE
35 aspirin resistance 31.2 F5 F2
36 nephrosclerosis 31.2 MTHFR F3 F2 ACE
37 central retinal artery occlusion 31.2 SERPINC1 PLAT MTHFR F2
38 lipoprotein quantitative trait locus 31.2 PLAT NOS3 MTHFR LDLR FBN1 F3
39 familial hypercholesterolemia 31.2 NOS3 MTHFR LDLR F2 APOH ALOX5AP
40 migraine with aura 31.2 NOTCH3 NOS3 MTHFR F5 F2 ACE
41 hemopericardium 31.2 FBN1 F3 F2
42 vascular dementia 31.1 NOTCH3 MTHFR ACE
43 homocysteinemia 31.1 SERPINC1 NOS3 MTHFR FBN1 F5 F2
44 migraine with or without aura 1 31.1 NOTCH3 NOS3 MTHFR MT-TL1 F2 APOH
45 thrombophilia 31.1 SERPINC1 PLAT MTHFR F5 F3 F2
46 protein s deficiency 31.1 SERPINC1 MTHFR F5 F3 F2 APOH
47 splenic infarction 31.1 SERPINC1 F3 F2 APOH
48 pericardial effusion 31.1 F3 F2 ACE
49 intracranial embolism 31.1 SERPINC1 PLAT F3 F2 ACE
50 intermediate coronary syndrome 31.1 SERPINC1 PLAT F3 ACE

Graphical network of the top 20 diseases related to Stroke, Ischemic:



Diseases related to Stroke, Ischemic

Symptoms & Phenotypes for Stroke, Ischemic

Human phenotypes related to Stroke, Ischemic:

31
# Description HPO Frequency HPO Source Accession
1 stroke 31 HP:0001297

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neuro:
stroke
motor, sensory and/or cognitive function loss

Clinical features from OMIM®:

601367 (Updated 20-May-2021)

UMLS symptoms related to Stroke, Ischemic:


seizures; tremor; back pain; angina pectoris; chest pain; headache; syncope; edema; pain; chronic pain; sciatica; vertigo/dizziness; equilibration disorder; sleeplessness

MGI Mouse Phenotypes related to Stroke, Ischemic:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACE ACSL4 ALOX5AP APOH F2 F3
2 growth/size/body region MP:0005378 10.3 ACE ACSL4 F2 F3 F5 FBN1
3 cardiovascular system MP:0005385 10.27 ACE ACSL4 F2 F3 F5 FBN1
4 mortality/aging MP:0010768 10.2 ACE ACSL4 APOH F2 F3 F5
5 endocrine/exocrine gland MP:0005379 10.18 ACE ACSL4 F2 FBN1 LDLR NOS3
6 immune system MP:0005387 10.18 ACE ALOX5AP F2 F3 FBN1 LDLR
7 integument MP:0010771 10.07 F2 F3 F5 FBN1 LDLR MTHFR
8 nervous system MP:0003631 9.97 ACE F2 F3 F5 FBN1 LDLR
9 muscle MP:0005369 9.91 F2 F3 FBN1 LDLR NOS3 NOTCH3
10 reproductive system MP:0005389 9.65 ACE ACSL4 F2 FBN1 MTHFR NOS3
11 vision/eye MP:0005391 9.32 ACE F3 LDLR MTHFR NOS3 NOTCH3

Drugs & Therapeutics for Stroke, Ischemic

PubMed Health treatment related to Stroke, Ischemic: 62

Treatment for a stroke depends on whether it is ischemic or hemorrhagic. Treatment for a transient ischemic attack (TIA) depends on its cause, how much time has passed since symptoms began, and whether you have other medical conditions. Strokes and TIAs are medical emergencies. If you have stroke symptoms, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts. Once you receive initial treatment , your doctor will try to treat your stroke risk factors and prevent complications.

Drugs for Stroke, Ischemic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 713)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
2
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
3
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Edaravone Approved, Investigational Phase 4 89-25-8 70335
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Dipyridamole Approved Phase 4 58-32-2 3108
8
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
9
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
10
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
11
Galantamine Approved Phase 4 357-70-0 9651
12
Losartan Approved Phase 4 114798-26-4 3961
13
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
14
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
15
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
16
Pantoprazole Approved Phase 4 102625-70-7 4679
17
Triflusal Approved, Investigational Phase 4 322-79-2
18
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
19
Atenolol Approved Phase 4 29122-68-7 2249
20
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
21
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
22
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
23
Dronedarone Approved Phase 4 141626-36-0, 141625-93-6 154087
24
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
25
Saxagliptin Approved Phase 4 361442-04-8 11243969
26
Flecainide Approved, Withdrawn Phase 4 54143-55-4 3356
27
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
28
Propafenone Approved Phase 4 54063-53-5 4932
29
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
30
Ticlopidine Approved Phase 4 55142-85-3 5472
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
32
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
33
Apixaban Approved Phase 4 503612-47-3 10182969
34
Etomidate Approved Phase 4 33125-97-2 36339 667484
35
Succinylcholine Approved Phase 4 306-40-1 5314
36
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
37
Probucol Approved, Investigational Phase 4 23288-49-5 4912
38
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
39
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
40
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
41
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
44
Labetalol Approved Phase 4 36894-69-6 3869
45
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
46
Nitric Oxide Approved Phase 4 10102-43-9 145068
47
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
48
Desflurane Approved Phase 4 57041-67-5 42113
49
Pravastatin Approved Phase 4 81093-37-0 54687
50
Baclofen Approved Phase 4 1134-47-0 2284

Interventional clinical trials:

(show top 50) (show all 5606)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
2 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
3 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
4 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
5 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
6 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
7 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
8 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
9 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
10 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
11 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
12 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
13 Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke Unknown status NCT03686163 Phase 4 Nerve Growth Factors;normal saline
14 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
15 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
16 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
17 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
18 The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels Unknown status NCT01926834 Phase 4 Erigeron Injection;placebo
19 The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein Unknown status NCT02562183 Phase 4 kallikrein
20 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
21 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
22 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
23 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
24 TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT Unknown status NCT03529149 Phase 4
25 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
26 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
27 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
28 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
29 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
30 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
31 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
32 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
33 A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH) Unknown status NCT00699465 Phase 4 enoxaparin;enoxaparin placebo
34 A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent) Unknown status NCT00954707 Phase 4 Clopidogrel & Aspirin, Prasugrel & Aspirin;Placebo & Aspirin
35 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Unknown status NCT01444508 Phase 4 Ringer-lactate "SAD";HES 130/04
36 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
37 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
38 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
39 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
40 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
41 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Unknown status NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
42 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
43 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
44 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
45 Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling Unknown status NCT02224131 Phase 4 Aspirin and clopidogrel;Aspirin and clopidogrel
46 Research Assistant Doctor Unknown status NCT03860662 Phase 4 Botox;Baclofen
47 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
48 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
49 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
50 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill

Search NIH Clinical Center for Stroke, Ischemic

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Dantrolene
Dantrolene Sodium
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Stroke, Ischemic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Stroke, Ischemic:
ALD-401, bone marrow-derived cells for stroke
Autologous bone marrow-derived mononuclear cells for treatment of acute ischemic stroke
Bone marrow-derived mononuclear cells for ischemic stroke
Bone marrow-derived mononuclear cells for ischemic stroke
Cerecellgram-Stroke, bone marrow-derived mesenchymal stem cells for treatment of ischemic stroke
Embryonic stem cell-derived neural stem cells for ischemic stroke
Mesenchymal stem cell-derived neuronal progenitor cells for the treatment of ischemic brain damage
Mesenchymal stem cells for ischemic stroke
MultiStem, bone marrow-derived cells for ischemic and neonatal stroke
NSI-566, spinal cord stem cells for neurological disorders
Olfactory ensheathing cells transplantion for treatment of old stroke ischemic patients
PDA001, Placenta-derived cells for ischemic stroke
ReN001, human neural stem cells for the treatment of stroke
SB623, Notch1-transfected mesenchymal stem cells for stroke
Stemedyne-MSC, mesenchymal stem cells for ischemic stroke
Umbilical cord blood-derived CD34+ stem cells for treatment of chronic ischemic stroke
Umbilical cord-derived mesenchymal stem cells for treatment of stroke
Embryonic/Adult Cultured Cells Related to Stroke, Ischemic:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905
Bone marrow-derived mononuclear cells (family) PMIDs: 22960888
Bone marrow-derived mononuclear cells PMIDs: 17635049
Bone marrow-derived mononuclear cells PMIDs: 20395386 20629187
Bone marrow-derived mesenchymal stem cells (Cerecellgram-Stroke)
Neural stem cells PMIDs: 18286199
Neural progenitor cells PMIDs: 21300404
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 22952736 21175285
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Olfactory ensheathing cells
Placenta-derived cells
Neural stem cell line (CTX0E03) PMIDs: 19633272 23185625 17981710
Notch-transfected mesenchymal stromal cells (SB623) PMIDs: 19530164 23430693 20350349 21982515
Trophic factor-induced mesenchymal stem cells PMIDs: 19530164 23430693 20350349 21982515
Bone marrow-derived mesenchymal stem cells (Stemedyne-MSC, itMSC) PMIDs: 23295150
Umbilical cord blood-derived hematopoietic stem cells (family)
Umbilical cord-derived mesenchymal stem cells

Cochrane evidence based reviews: cerebral infarction

Genetic Tests for Stroke, Ischemic

Genetic tests related to Stroke, Ischemic:

# Genetic test Affiliating Genes
1 Ischemic Stroke, Susceptibility to 29 ALOX5AP F2 F5 NOS3 PRKCH
2 Cerebral Infarction, Susceptibility to 29

Anatomical Context for Stroke, Ischemic

MalaCards organs/tissues related to Stroke, Ischemic:

40
Brain, Heart, Bone Marrow, Bone, Endothelial, Cortex, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Stroke, Ischemic:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate

Publications for Stroke, Ischemic

Articles related to Stroke, Ischemic:

(show top 50) (show all 32303)
# Title Authors PMID Year
1
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 6 57 54
15534175 2004
2
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 57 6
17165044 2007
3
A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. 6 57
17206144 2007
4
A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. 54 57
20378606 2010
5
Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. 57 54
16550187 2006
6
Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. 57 54
16286536 2006
7
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. 54 57
16115816 2005
8
Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. 57 54
15640973 2005
9
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 54 6
15277638 2004
10
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. 57 54
14770184 2004
11
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. 54 57
14681304 2004
12
Verification and comparison of three prediction models of ischemic stroke in young adults based on the back propagation neural networks. 42 61
33725985 2021
13
Study on quantitative diagnosis model of TCM syndromes of post-stroke depression based on combination of disease and syndrome. 61 42
33761663 2021
14
Chinese herbal injections combined with rt-PA intravenous thrombolysis for acute ischemic stroke: A systematic review and meta-analysis protocol. 42 61
33725879 2021
15
Association between lncRNA ANRIL genetic variants with the susceptibility to ischemic stroke: From a case-control study to meta-analysis. 42 61
33725991 2021
16
Effectiveness and safety of music-supported therapy on mood in post-stroke rehabilitation patients: A protocol for systematic review and meta-analysis. 42 61
33761665 2021
17
Predictors of Instrumental Activities of Daily Living Performance in Patients with Stroke. 61 42
33727902 2021
18
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
19
Association study of the polymorphisms on chromosome 12p13 with atherothrombotic stroke in the Japanese population. 57
20448654 2010
20
Failure to validate association between 12p13 variants and ischemic stroke. 57
20410525 2010
21
Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. 57
20042462 2010
22
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. 6
19531787 2009
23
Genomewide association studies of stroke. 57
19369658 2009
24
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
25
Genetically elevated C-reactive protein and ischemic vascular disease. 57
18971492 2008
26
Genetic polymorphisms for the study of multifactorial stroke. 57
18421701 2008
27
Linking Notch signaling to ischemic stroke. 57
18347334 2008
28
Telomere length predicts poststroke mortality, dementia, and cognitive decline. 57
16685698 2006
29
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 6
16813604 2006
30
Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. 6
16493002 2006
31
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 57
16043803 2005
32
R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. 6
15638861 2005
33
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 6
16059745 2005
34
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
35
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
36
ACE1 polymorphism and progression of SARS. 6
15381116 2004
37
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
38
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. 6
14996674 2004
39
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 6
15007011 2004
40
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
41
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
42
Genetics of common polygenic stroke. 57
14517535 2003
43
Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. 6
12958323 2003
44
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
45
New players in the genetics of stroke. 57
12444190 2002
46
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
47
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
48
Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. 6
11796466 2002
49
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 6
11687636 2001
50
Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden--an evolutionary advantage? 6
11686338 2001